Praxis Precision Medicines, Inc.

For the period ended Dec 31, 2025. Filed Feb 19, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 19, 2026

PRAX$337.59+1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(Amounts in thousands, except share data)

Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · Accumulated Other Comprehensive Gain (Loss) · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 2022	3,292,163	$5	$606,918	$(530,644)	$(173)	$76,106
Stock-based compensation expense	—	—	24,857	—	—	24,857
Issuance of common stock from follow-on public offering and accompanying pre-funded warrants, net of underwriting discounts, commissions and offering costs of $4,484	4,296,646	6	63,433	—	—	63,439
Issuance of common stock from at-the-market public offerings, net of issuance and commission costs of $683	1,165,247	2	28,090	—	—	28,092
Issuance of common stock under employee stock purchase plan	24,690	—	314	—	—	314
Vesting of restricted stock units	13,293	—	—	—	—	—
Shares withheld for taxes for vesting of restricted stock units	(3,443)	—	(137)	—	—	(137)
Issuance of common stock upon exercise of stock options	3,281	—	102	—	—	102
Change in unrealized gain (loss) on marketable securities, net of tax	—	—	—	—	173	173
Net loss	—	—	—	(123,277)	—	(123,277)
Balance at December 31, 2023	8,791,877	$13	$723,577	$(653,921)	$—	$69,669
Stock-based compensation expense	—	—	41,360	—	—	41,360
Issuance of common stock from follow-on public offering and accompanying pre-funded warrants, net of underwriting discounts, commissions and offering costs of $24,849	7,651,583	1	377,636	—	—	377,637
Issuance of common stock from at-the-market public offerings, net of issuance and commission costs of $3,258	1,823,652	—	119,359	—	—	119,359
Issuance of common stock from exercise of pre-funded warrants	622,123	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	31,381	—	544	—	—	544
Issuance of common stock from a collaboration and license agreement	443,253	—	17,265	—	—	17,265
Vesting of restricted stock units	19,475	—	—	—	—	—
Shares withheld for taxes for vesting of restricted stock units	(6,163)	—	(308)	—	—	(308)
Issuance of common stock upon exercise of stock options	45,177	—	2,089	—	—	2,089
Change in unrealized gain (loss) on marketable securities, net of tax	—	—	—	—	654	654
Net loss	—	—	—	(182,819)	—	(182,819)
Balance at December 31, 2024	19,422,358	$14	$1,281,522	$(836,740)	$654	$445,450
Stock-based compensation expense	—	—	33,941	—	—	33,941
Issuance of common stock from follow-on public offering and accompanying pre-funded warrants, net of underwriting discounts, commissions and offering costs of $36,635	3,527,072	1	567,115	—	—	567,116
Issuance of common stock from at-the-market public offerings, net of issuance and commission costs of $2,767	1,755,636	—	123,803	—	—	123,803
Issuance of common stock from exercise of pre-funded warrants	200,349	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	22,691	—	717	—	—	717
Vesting of restricted stock units	78,281	—	—	—	—	—
Shares withheld for taxes for vesting of restricted stock units	(24,333)	—	(2,089)	—	—	(2,089)
Issuance of common stock upon exercise of stock options	213,038	—	12,557	—	—	12,557
Change in unrealized gain (loss) on marketable securities, net of tax	—	—	—	—	(91)	(91)
Net loss	—	—	—	(303,268)	—	(303,268)
Balance at December 31, 2025	25,195,092	$15	$2,017,566	$(1,140,008)	$563	$878,136

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.